BCBS-SC: Humira Biosimilars Replacing Humira (brand) Effective January 1, 2025
Beginning January 1, 2025, Humira (brand) will be removed from BlueCross BlueShield of South Carolina and BlueChoice HealthPlan’s Lowest Net Cost, Exchange and Premium formularies. Adalimumab biosimilars will instead be the preferred products for each of these formularies. Humira biosimilars are designed to be biologically similar to the reference medication and are just as safe and effective. […]